Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCB 008

Next Previous
Drug Profile

TCB 008

Alternative Names: Gamma delta T cell lymphocyte - TC Biopharm; TCB-008; unmodified expanded gamma delta T cell Lymphocytes

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TC BioPharm
  • Developer Queen Mary University of London; TC BioPharm
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Mucositis
  • No development reported COVID 2019 infections

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in United Kingdom (IV, Injection)
  • 16 Jan 2025 TC BioPharm plans a preclinical studies for Influenza A virus H1N1 subtype
  • 11 Dec 2024 TC BioPharm has partnered with CareDx for pharmacokinetic monitoring of TCB008 in the ACHIEVE clinical trial for Acute Myeloid Leukemia and Myelodysplastic Syndrome .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top